Smith Group Asset Management’s Haemonetics HAE Stock Holding History

Smith Group Asset Management’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-23,780	Closed	-$2.38M	–	457
2018 Q4	$2.38M	Sell	23,780 -1,820	-7%	-$191K	0.08%	111
2018 Q3	$2.93M	Sell	25,600 -2,940	-10%	-$304K	0.08%	110
2018 Q2	$2.56M	Sell	28,540 -4,270	-13%	-$361K	0.07%	116
2018 Q1	$2.4M	Sell	32,810 -27,700	-46%	-$1.9M	0.08%	113
2017 Q4	$3.51M	Buy	+60,510	New	+$3.19M	0.11%	126
2014 Q2	–	Sell	-184	Closed	-$6K	–	428
2014 Q1	$6K	Hold	184	–	–	﹤0.01%	355
2013 Q4	$8K	Hold	184	–	–	﹤0.01%	334
2013 Q3	$7K	Hold	184	–	–	﹤0.01%	368
2013 Q2	$8K	Buy	+184	New	+$7.45K	﹤0.01%	359

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Smith Group Asset Management's HAE Position: Q1 2019 in Review

Smith Group Asset Management sold out of Haemonetics (HAE) in Q1 2019, closing a stake of 23,780 shares — an estimated $2.38M sold.

Smith Group Asset Management first reported a position in HAE in Q2 2013 and held it in 9 quarters. The position peaked at $3.51M in Q4 2017. 260 funds tracked by Wall St. Rank hold HAE as of Q1 2019.

Smith Group Asset Management reported no remaining Haemonetics position as of Q1 2019 after selling out during the quarter.
Smith Group Asset Management sold 23,780 Haemonetics shares in Q1 2019, an estimated $2.38M.
Smith Group Asset Management first reported a position in Haemonetics in Q2 2013 and held it in 9 quarters.
Smith Group Asset Management's Haemonetics position peaked at $3.51M in Q4 2017.
260 funds tracked by Wall St. Rank held Haemonetics as of Q1 2019.

Based on Smith Group Asset Management's 13F filing for Q1 2019, filed 10 May 2019.